Chronic treatment with recombinant human erythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin-induced diabetic rat

European Journal of Pharmacology

Volumn 612, Issue 1-3, 2009, Pages 106-114

  Toba, Hiroe ^a   Sawai, Naoki ^a   Morishita, Masayuki ^a   Murata, Shoko ^a   Yoshida, Mamiko ^a   Nakashima, Kohei ^a   Morita, Yosuke ^a   Kobara, Miyuki ^a   Nakata, Tetsuo ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Diabetic nephropathy; Erythropoietin

Indexed keywords

CELL ADHESION MOLECULE; CREATININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE 3BETA; MESSENGER RNA; OSTEOPONTIN; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BLOOD PRESSURE; COLLAGEN METABOLISM; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HEMATOCRIT; HEMATOPOIESIS; MALE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION; REPERFUSION INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION;

ANIMALS; APOPTOSIS; BLOOD GLUCOSE; BLOOD UREA NITROGEN; CELL DEATH; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; GLYCOGEN SYNTHASE KINASE 3; HEMATOCRIT; HEMATOPOIESIS; HUMANS; IN SITU NICK-END LABELING; KIDNEY; MALE; NADPH OXIDASE; OSTEOPONTIN; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RANDOM ALLOCATION; RATS; RATS, WISTAR; RNA, MESSENGER; SIGNAL TRANSDUCTION; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 65549121743     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.03.065     Document Type: Article

References (41)

1. Alessi D.R., and Cohen P. Mechanism of activation and function of protein kinase B. Curr Opin. Genet. Dev. 8 (1998) 55-62
2. Asaba K., Tojo A., Onozato M.L., Goto A., Quinn M.T., Fujita T., and Wilcox C.S. Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int. 67 (2005) 1890-1898
3. Bahlmann F.H., Song R., Boehm S.M., Mengel M., von Wasielewski R., Lindschau C., Kirsch T., de Groot K., Laudeley R., Niemczyk E., Guler F., Menne J., Haller H., and Fliser D. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 110 (2004) 1006-1012 Electronic publication 2004 Aug 1009
4. Banba N., Nakamura T., Matsumura M., Kuroda H., Hattori Y., and Kasai K. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int. 58 (2000) 684-690
5. Baylis C., Mitruka B., and Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J. Clin. Invest. 90 (1992) 278-281
6. Baynes J.W. Role of oxidative stress in development of complications in diabetes. Diabetes 40 (1991) 405-412
7. Bilous R.W., Mauer S.M., Sutherland D.E., and Steffes M.W. Mean glomerular volume and rate of development of diabetic nephropathy. Diabetes 38 (1989) 1142-1147
8. Borch-Johnsen K., and Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br. Med. J. (Clin. Res. Ed.) 294 (1987) 1651-1654
9. Burger D., Lei M., Geoghegan-Morphet N., Lu X., Xenocostas A., and Feng Q. Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc. Res. 72 (2006) 51-59 Electronic publication 2006 Jun 2030
10. Cai Z., and Semenza G.L. Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation 109 (2004) 2050-2053 Electronic publication 2004 Apr 2026
11. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 296 (2002) 1655-1657
12. Cetin H., Olgar S., Oktem F., Ciris M., Uz E., Aslan C., and Ozguner F. Novel evidence suggesting an anti-oxidant property for erythropoietin on vancomycin-induced nephrotoxicity in a rat model. Clin. Exp. Pharmacol. Physiol. 34 (2007) 1181-1185
13. Chatterjee P.K. Pleiotropic renal actions of erythropoietin. Lancet 365 (2005) 1890-1892
14. Chong Z.Z., Kang J.Q., and Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 106 (2002) 2973-2979
15. d'Uscio L.V., Smith L.A., Santhanam A.V., Richardson D., Nath K.A., and Katusic Z.S. Essential role of endothelial nitric oxide synthase in vascular effects of erythropoietin. Hypertension 49 (2007) 1142-1148 Electronic publication 2007 Mar 1119
16. Deckert T., Poulsen J.E., and Larsen M. Prognosis of diabetics with diabetes onset before the age of thirty-one. I. Survival, causes of death, and complications. Diabetologia 14 (1978) 363-370
17. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell. Biol. 10 (1998) 262-267
18. Hinokio Y., Suzuki S., Hirai M., Chiba M., Hirai A., and Toyota T. Oxidative DNA damage in diabetes mellitus: its association with diabetic complications. Diabetologia 42 (1999) 995-998
19. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol. Rev. 72 (1992) 449-489
20. Katavetin P., Inagi R., Miyata T., Shao J., Sassa R., Adler S., Eto N., Kato H., Fujita T., and Nangaku M. Erythropoietin induces heme oxygenase-1 expression and attenuates oxidative stress. Biochem. Biophys. Res. Commun. 359 (2007) 928-934 Electronic publication 2007 Jun 2006
21. Katavetin P., Tungsanga K., Eiam-Ong S., and Nangaku M. Antioxidative effects of erythropoietin. Kidney Int. Suppl. (2007) S10-15
22. Khoshdel A., Carney S., Gillies A., Mourad A., Jones B., Nanra R., and Trevillian P. Potential roles of erythropoietin in the management of anaemia and other complications diabetes. Diabetes Obes. Metab. 10 (2008) 1-9 Electronic publication 2007 Jul 2021
23. Mitra A., Bansal S., Wang W., Falk S., Zolty E., and Schrier R.W. Erythropoietin ameliorates renal dysfunction during endotoxaemia. Nephrol. Dial. Transplant. 22 (2007) 2349-2353 Electronic publication 2007 Apr 2316
24. Miyake T., Kung C.K., and Goldwasser E. Purification of human erythropoietin. J. Biol. Chem. 252 (1977) 5558-5564
25. Mogensen C.E., and Christensen C.K. Predicting diabetic nephropathy in insulin-dependent patients. N. Engl. J. Med. 311 (1984) 89-93
26. Nakagawa T., Sato W., Glushakova O., Heinig M., Clarke T., Campbell-Thompson M., Yuzawa Y., Atkinson M.A., Johnson R.J., and Croker B. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J. Am. Soc. Nephrol. 18 (2007) 539-550 Electronic publication 2007 Jan 2003
27. Patel N.S., Sharples E.J., Cuzzocrea S., Chatterjee P.K., Britti D., Yaqoob M.M., and Thiemermann C. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int. 66 (2004) 983-989
28. Sano T., Umeda F., Hashimoto T., Nawata H., and Utsumi H. Oxidative stress measurement by in vivo electron spin resonance spectroscopy in rats with streptozotocin-induced diabetes. Diabetologia 41 (1998) 1355-1360
29. Santhanam A.V., Smith L.A., Nath K.A., and Katusic Z.S. In vivo stimulatory effect of erythropoietin on endothelial nitric oxide synthase in cerebral arteries. Am. J. Physiol. Heart Circ. Physiol. 291 (2006) H781-786 Electronic publication 2006 Mar 2024
30. Sassy-Prigent C., Heudes D., Mandet C., Belair M.F., Michel O., Perdereau B., Bariety J., and Bruneval P. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 49 (2000) 466-475
31. Schnackenberg C.G. Oxygen radicals in cardiovascular-renal disease. Curr. Opin. Pharmacol. 2 (2002) 121-125
32. Schneider A., Panzer U., Zahner G., Wenzel U., Wolf G., Thaiss F., Helmchen U., and Stahl R.A. Monocyte chemoattractant protein-1 mediates collagen deposition in experimental glomerulonephritis by transforming growth factor-beta. Kidney Int. 56 (1999) 135-144
33. Sharples E.J., Patel N., Brown P., Stewart K., Mota-Philipe H., Sheaff M., Kieswich J., Allen D., Harwood S., Raftery M., Thiemermann C., and Yaqoob M.M. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J. Am. Soc. Nephrol. 15 (2004) 2115-2124
34. Singh D.K., Winocour P., and Farrington K. Mechanisms of disease: the hypoxic tubular hypothesis of diabetic nephropathy. Nat. Clin. Pract. Nephrol. 4 (2008) 216-226 Electronic publication 2008 Feb 2012
35. Thallas-Bonke V., Thorpe S.R., Coughlan M.T., Fukami K., Yap F.Y., Sourris K.C., Penfold S.A., Bach L.A., Cooper M.E., and Forbes J.M. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 57 (2008) 460-469 Electronic publication 2007 Oct 2024
36. Viberti G.C., Hill R.D., Jarrett R.J., Argyropoulos A., Mahmud U., and Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1 (1982) 1430-1432
37. Yamasowa H., Shimizu S., Inoue T., Takaoka M., and Matsumura Y. Endothelial nitric oxide contributes to the renal protective effects of ischemic preconditioning. J. Pharmacol. Exp. Ther. 312 (2005) 153-159 Electronic publication 2004 Aug 2012
38. Yang C.W., Li C., Jung J.Y., Shin S.J., Choi B.S., Lim S.W., Sun B.K., Kim Y.S., Kim J., Chang Y.S., and Bang B.K. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J. 17 (2003) 1754-1755 Electronic publication 2003 Jul 1718
39. Zeng G., Nystrom F.H., Ravichandran L.V., Cong L.N., Kirby M., Mostowski H., and Quon M.J. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 101 (2000) 1539-1545
40. Ziyadeh F.N., and Goldfarb S. The renal tubulointerstitium in diabetes mellitus. Kidney Int. 39 (1991) 464-475
41. Ziyadeh F.N., and Goldfarb S. The diabetic renal tubulointerstitium. Curr. Top. Pathol. 88 (1995) 175-201